vixarelimab   Click here for help

GtoPdb Ligand ID: 13451

Synonyms: KPL-716 | KPL716
Immunopharmacology Ligand
Compound class: Antibody
Comment: Vixarelimab (KPL-716) is an anti-oncostatin M (OSM) receptor β subunit monoclonal antibody [1]. It disrupts both interleukin-31 and OSM signalling at the interface between immune cells and connective tissue/stromal cells, by attenuating the MCP-1 response to OSM. The effects of vixarelimab are distinct to those of an anti-IL-31 receptor α monoclonal.
No information available.
Summary of Clinical Use Click here for help
Vixarelimab (KPL-716) is a clinical candidate for inflammatory dermatologic diseases.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03858634 A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases Phase 2 Interventional Kiniksa Pharmaceuticals, Ltd.
NCT03816891 Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis Phase 2 Interventional Kiniksa Pharmaceuticals, Ltd.
NCT06137183 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC) Phase 2 Interventional Genentech, Inc.
NCT05785624 A Study Evaluating the Efficacy and Safety of Vixarelimab in Participants With Idiopathic Pulmonary Fibrosis and in Participants With Systemic Sclerosis-Associated Interstitial Lung Disease Phase 2 Interventional Genentech, Inc.